Pandora Wealth Inc. Acquires New Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Key Points

• Pandora Wealth Inc. has invested approximately $3.3 million in TG Therapeutics, Inc. (NASDAQ:TGTX), acquiring 83,700 shares, making it the firm's 11th largest holding.
• A variety of investors, including NBC Securities Inc. and Golden State Wealth Management LLC, have significantly increased their stakes in TG Therapeutics, with institutional investors currently owning 58.58% of the stock.
• TG Therapeutics reported $0.17 earnings per share for the last quarter, missing estimates of $0.32, while also showing a 92.1% increase in revenue year-over-year.

Pandora Wealth Inc. bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 83,700 shares of the biopharmaceutical company's stock, valued at approximately $3,300,000. TG Therapeutics comprises approximately 2.2% of Pandora Wealth Inc.'s investment portfolio, making the stock its 11th largest holding. Pandora Wealth Inc. owned 0.05% of TG Therapeutics at the end of the most recent quarter.

Several other large investors have also bought and sold shares of TGTX. O Shaughnessy Asset Management LLC bought a new position in TG Therapeutics during the 4th quarter worth $259,000. Wells Fargo & Company MN increased its position in TG Therapeutics by 85.4% in the 4th quarter. Wells Fargo & Company MN now owns 331,403 shares of the biopharmaceutical company's stock valued at $9,975,000 after buying an additional 152,682 shares in the last quarter. Envestnet Asset Management Inc. increased its position in TG Therapeutics by 11.4% in the 4th quarter. Envestnet Asset Management Inc. now owns 50,111 shares of the biopharmaceutical company's stock valued at $1,508,000 after buying an additional 5,135 shares in the last quarter. Russell Investments Group Ltd. increased its position in TG Therapeutics by 323.2% in the 4th quarter. Russell Investments Group Ltd. now owns 34,706 shares of the biopharmaceutical company's stock valued at $1,045,000 after buying an additional 26,506 shares in the last quarter. Finally, Quadrant Capital Group LLC boosted its stake in TG Therapeutics by 137.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock valued at $51,000 after purchasing an additional 975 shares during the last quarter. 58.58% of the stock is owned by institutional investors.

Insider Buying and Selling at TG Therapeutics

In other news, Director Yann Echelard sold 10,000 shares of the business's stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $36.94, for a total value of $369,400.00. Following the transaction, the director owned 228,816 shares in the company, valued at $8,452,463.04. The trade was a 4.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.64% of the stock is owned by insiders.

Analyst Ratings Changes

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 price target for the company in a research note on Thursday, July 10th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, TG Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $46.25.

TG Therapeutics Stock Up 2.8%

TGTX stock traded up $0.75 during mid-day trading on Wednesday, reaching $27.87. 1,479,276 shares of the company traded hands, compared to its average volume of 2,513,994. The stock has a market cap of $4.42 billion, a price-to-earnings ratio of 75.43 and a beta of 1.95. The company has a quick ratio of 3.04, a current ratio of 3.86 and a debt-to-equity ratio of 0.89. TG Therapeutics, Inc. has a fifty-two week low of $20.39 and a fifty-two week high of $46.48. The firm's 50 day moving average price is $35.72 and its 200 day moving average price is $35.95.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%. The business had revenue of $141.15 million during the quarter, compared to analysts' expectations of $147.76 million. During the same quarter in the previous year, the firm earned $0.04 EPS. TG Therapeutics's quarterly revenue was up 92.1% on a year-over-year basis. As a group, equities research analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.